Revolutionary treatment offers new hope to Russian cancer patients

11 February 2009

Two of Russia’s leading research centers, The Meshalkin Research Institute of Circulation Pathology (NRIBCP, Novosibirsk, Russia) and the Hertzen Moscow Oncology Research Institute (MORI, Moscow, Russia), have purchased Elekta Axesse systems which will, for the first time in Russia, allow clinicians to treat cancer tumours throughout the body with ultra-high precision while minimizing damage to surrounding healthy tissue.

“Elekta Axesse will help us to build the one of the most advanced cancer centres in Russia,” says Professor Alexander M. Karaskov, Director of the Meshalkin Research Institute. “The system combines speed and accuracy with the ability to target tumours throughout the body.”

Elekta Axesse will be delivered with the latest technology, Elekta VMAT (Volumetric Modulated Arc Therapy), which enables faster treatment time and more accurate targeting of the dose. Hertzen MORI will be the first clinic in Russia to provide this technology to patients.

“The system will enable us to attain very-high precision and accuracy for every patient, in many cases sub-millimetre. This is specifically important in treatment of difficult sites such as lung or liver,” commented Professor Anna Boyko from MORI. “The advanced 3D imaging capabilities of Elekta Axesse facilitate rapid, precise targeting of tumours, and the highly-conformal radiation delivery system effectively treats tumours while minimizing damage to a patient’s healthy tissue.”

This advanced technology is delivered with MOSAIQ, the most advanced integrated suite of Electronic Medical Record (EMR) software in oncology; which enhances workflow, improves productivity and simplifies medical record accessibility throughout the department.

“Software support for efficient workflow is a key component in a treatment system and MOSAIQ, along with the entire software package supplied by Elekta, is second to none. In a clinical setting, the system manages documents, patient and user schedules and imports treatment plans into the EMR as well as verifies and records the treatment delivered, all handled from one integrated user environment. This definitely helps to streamline clinicians’ workflow, ultimately saving precious time,” said Dr Olga Efimova, NRIBCP’s Head of Radiosurgery.

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Revolutionary treatment offers new hope to Russian cancer patients 11 February 2009 Two of Russia’s leading research centers, The Meshalkin Research Institute of Circulation Pathology (NRIBCP, Novosibirsk, Russia) and the Hertzen Moscow Oncology Research Institute (MORI, Moscow, Russia), have purchased Elekta Axesse systems which will, for the first time in Russia, allow clinicians to treat cancer tumours throughout the body with ultra-high precision while minimizing damage to surrounding healthy tissue. “Elekta Axesse will help us to build the one of the most advanced cancer centres in Russia,” says Professor Alexander M. Karaskov, Director of the Meshalkin Research Institute. “The system combines speed and accuracy with the ability to target tumours throughout the body.” Elekta Axesse will be delivered with the latest technology, Elekta VMAT (Volumetric Modulated Arc Therapy), which enables faster treatment time and more accurate targeting of the dose. Hertzen MORI will be the first clinic in Russia to provide this technology to patients. “The system will enable us to attain very-high precision and accuracy for every patient, in many cases sub-millimetre. This is specifically important in treatment of difficult sites such as lung or liver,” commented Professor Anna Boyko from MORI. “The advanced 3D imaging capabilities of Elekta Axesse facilitate rapid, precise targeting of tumours, and the highly-conformal radiation delivery system effectively treats tumours while minimizing damage to a patient’s healthy tissue.” This advanced technology is delivered with MOSAIQ, the most advanced integrated suite of Electronic Medical Record (EMR) software in oncology; which enhances workflow, improves productivity and simplifies medical record accessibility throughout the department. “Software support for efficient workflow is a key component in a treatment system and MOSAIQ, along with the entire software package supplied by Elekta, is second to none. In a clinical setting, the system manages documents, patient and user schedules and imports treatment plans into the EMR as well as verifies and records the treatment delivered, all handled from one integrated user environment. This definitely helps to streamline clinicians’ workflow, ultimately saving precious time,” said Dr Olga Efimova, NRIBCP’s Head of Radiosurgery. Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.